Key Stats for Merck Stock
- Price change for Merck stock: 6%
- $MRK Share Price as of May. 22: $122
- 52-Week High: $125
- $MRK Stock Price Target: $130
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Merck (MRK) stock jumped 5.6% on Friday, closing at $122.41. Two separate cancer treatment developments drove the move.
- First, European health officials recommended approving Merck’s Keytruda and Padcev combination for patients with muscle-invasive bladder cancer.
- This matters because many of these patients — often elderly or too sick for harsh chemotherapy — currently have very few treatment options.
- The recommendation brings Merck closer to offering a Keytruda-based regimen for this group, both before and after surgery.
- Second, and arguably more exciting for investors, Merck released late-stage trial results for a drug called Sac-TMT.
- Merck licensed this ADC from China’s Kelun Pharma back in 2022.
- ADCs work by attaching toxic payloads to antibodies, directing chemotherapy-like damage directly at cancer cells while reducing harm to nearby healthy tissue.
When Sac-TMT was combined with Keytruda and compared with Keytruda alone in lung cancer patients, 70% responded to the combination. That compares favorably with the 56%-58% response rate observed with standard chemo-plus-Keytruda regimens.
The combination also cut the risk of disease progression by 53% in patients with high levels of the PD-1 protein — the same protein Keytruda is designed to block.
See analysts’ growth forecasts and price targets for Merck stock (It’s free) >>>
What the Market Is Telling Us About Merck Stock
Merck stock has faced a real question mark for years: what happens when Keytruda, its biggest drug, loses patent exclusivity? Keytruda is a massive revenue driver, and investors have been closely watching for its replacement.
Sac-TMT is one of the clearest answers Merck has offered so far. Leerink Partners analyst Daina Graybosch noted the results met expectations and support Merck’s “bio-better chemo” strategy.
She also pointed out that investors have been underwhelmed by Sac-TMT until now, which helps explain why Friday’s results moved Merck stock so sharply.
The MIBC bladder cancer approval in Europe adds another near-term revenue opportunity on top of that.
Merck stock remains close to its 52-week high, but Friday’s move suggests the market is starting to price in a more diversified oncology pipeline — one that doesn’t rely entirely on Keytruda alone.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Merck Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
